Compare BioNano Genomics Inc (BNGO) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs DuPont de Nemours Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while DuPont de Nemours Inc trades at $144.26 (market cap $19.51B). The key difference: DuPont de Nemours Inc is far larger — about 1428.3× BioNano Genomics Inc's market cap, and DuPont de Nemours Inc pays a 1.66% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DD | |
|---|---|---|
Market Cap | $13.66M | $19.51B |
Sector | Health | Basic Materials |
52-Week High | $4.92 | $154.59 |
52-Week Low | $1.06 | $90.24 |
Enterprise Value | $16.26M | $20.90B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
DuPont (DD) trades at $141.56, down 0.65% over the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and aerospace demand, leading to a raised full-year 2026 outlook. The stock exhibits a high P/E ratio of 62.01, reflecting growth expectations, while net income margin remains thin at 0.79%.
Outlook is positive due to earnings momentum and strategic initiatives in water treatment and lithium extraction, but risks include legal settlements over PFAS chemicals and volatile cash flows. With a consensus price target of $232.80 implying significant upside, the stock offers growth potential tempered by execution and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
